Innovative SolutIons for DosimEtry in Hadrontherapy (INSIDE) (INSIDE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03662373|
Recruitment Status : Recruiting
First Posted : September 7, 2018
Last Update Posted : July 21, 2020
The study aim is to test the clinical feasibility and effectiveness of an online qualitative monitoring device named INSIDE system during hadrontherapy treatments.
This instrumentation is composed by detectors able to acquire secondary signals generated by the interaction of the primary beam with human tissues. From these measurements performed during irradiation, the INSIDE system estimates the particle beam range inside the patient's body and check the compliance of the ongoing treatment with the clinical prescription, with the aim to optimize the delivered dose.
The study aims to longitudinally monitor patients treated with hadrontherapy at the Italian National Centre of Oncological Hadrontherapy (CNAO) in Pavia in order to:
- evaluate the stability of the INSIDE system response and the significance of the monitoring measurement;
- study the clinical tolerances between ongoing and prescribed treatments within which the differences in particle range are not clinically relevant;
- assess what impact an instrument such as the INSIDE system can have on the clinical routine;
- evaluate the benefits of such a monitoring system with respect to treatment planning constraints.
|Condition or disease||Intervention/treatment|
|Particle Therapy||Radiation: carbon ions radiation therapy Radiation: protons radiation therapy|
A treatment monitoring instrumentation is highly demanded to maximize the benefits of hadrontherapy from the increased conformation of the released dose to the tumor volume with respect to the conventional radiotherapy.
Since almost all the energy of the charged particles is deposited in the end of their track (Bragg Peak region), the verification of the particle range by experimental measurements, performed during treatment delivery, can help to increase the therapy effectiveness while better sparing healthy tissues.
The INSIDE system is an innovative bi-modal instrumentation consisting of an in-beam Positron Emission Tomography (PET) scanner, to detect annihilation photons coming from positron isotope emitters, and a Dose Profiler to collect signals from charged particles emitted during treatment (e.g. protons in the case of carbon ion treatments).
The in-beam PET scanner is composed by two opposite panels of detectors placed above and below the patient bed, respectively. The Dose Profiler is positioned above the patient with an angle of 60°, forwardly with respect to the beam direction.
The INSIDE system is a passive instrumentation, i.e. no additional dose has to be released to the patient for particle range verification.
The INSIDE detectors are mounted on a mobile support and, immediately before the treatment delivery, they will be placed around the patient in the acquisition position, thanks to a dedicated hooking system designed to guarantee the maximum precision and accuracy in the particle range verification.
The INSIDE system mechanics is compatible with multi fields irradiation of patients affected by pathologies of Head-and-Neck and Brain districts.
In the clinical trial, patients affected by four selected pathologies will be included: meningioma and nasopharynx cancers treated with proton beams, Adenoid Cystic Carcinoma (ACC) and clival chordoma treated with carbon ion beams. These were chosen in order to study both projectile particles available at the CNAO centre (i.e., protons and carbon ions), and target specific pathologies which should most benefit from the range monitoring provided by the INSIDE system. Among them are cancers for which an early response is commonly observed and tumors which are located near cavities that can be filled with either water-like material (such as cancerous mass and inflamed tissues) or air.
The patients will undergo a longitudinal protocol of measurements in order to verify the agreement between the ongoing treatment and the prescription throughout the complete treatment period (lasting in average about 4-6 weeks for the selected pathologies).
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Sperimentazione Clinica Del Sistema INSIDE - Innovative SolutIons for DosimEtry in Hadrontherapy - Per il Monitoraggio Del Trattamento in Adroterapia|
|Actual Study Start Date :||July 16, 2019|
|Estimated Primary Completion Date :||December 31, 2020|
|Estimated Study Completion Date :||December 31, 2020|
carbon ions radiation therapy
the group of patients treated with carbon ion radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria
Radiation: carbon ions radiation therapy
Carbon ion radiation therapy to treat adenoid cystic carcinoma, skull base (clivus) chordoma.
Other Name: particle therapy
protons radiation therapy
the group of patients treated with proton radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria
Radiation: protons radiation therapy
Proton radiation therapy used to treat meningioma and squamocellular rhinopharynx carcinoma
Other Name: particle therapy
- particles ranges [ Time Frame: average of 5 weeks (as a treatment duration) ]evaluate the quality of treatments in term of data collection and of particles range evaluated with PET scanner and Monte Carlo simulations
- particles ranges for each pathology considered [ Time Frame: 4 months ]statistical analysis to assess the evaluations of treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03662373
|Contact: Viviana Vitolo, MDfirstname.lastname@example.org|
|Contact: Francesca Valvo, MDemail@example.com|
|Pavia, Italy, 27100|
|Contact: Cristina Bono, MSc +39(0)382078613 firstname.lastname@example.org|
|Principal Investigator:||Viviana Vitolo, MD||CNAO National Center of Oncological Hadrontherapy|